Church & Dwight Co., Inc. — Q1 2024 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2024, compared with Q1 2023. Church & Dwight sells household, personal care and specialty products through Consumer Domestic, Consumer International and Specialty Products Division (SPD). Figures below are in millions of dollars, except per-share data and percentages.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $1,503.3 | $1,429.8 | +5.1% |
| Gross profit / gross margin | $687.0 / 45.7% | $622.0 / 43.5% | +10.5% / +220 bps |
| Operating income / operating margin | $305.0 / 20.3% | $291.9 / 20.4% | +4.5% / -10 bps |
| Net income | $227.7 | $203.2 | +12.1% |
| Diluted EPS | $0.93 | $0.82 | +13.4% |
| Operating cash flow | $263.0 | $273.1 | -$10.1 |
| Capital expenditures | $46.3 | $25.0 | +$21.3 |
- Sales growth reflected 3.7% higher volume, 1.5% favorable price/product mix and 0.3% foreign exchange, partly offset by a 0.4% impact from exiting an SPD product line.
- Gross-margin improvement came from favorable price/mix/volume, productivity and lower transportation costs, partly offset by higher manufacturing costs and unfavorable foreign exchange. Marketing expense rose 24.3% to $152.0, and SG&A rose 10.7% to $230.0; management cited product-launch marketing, international growth investment and R&D.
- The effective tax rate fell to 19.9% from 24.4%, primarily due to benefits from higher stock-option exercises. Interest expense declined to $25.0 from $28.8, mainly due to lower average debt.
Liquidity, debt and capital allocation
- At March 31, cash and cash equivalents were $349.7; total current assets were $1,534.3 and current liabilities $1,151.1.
- Debt comprised $2,202.8 of long-term debt and $4.0 of short-term borrowings. The company repaid the remaining $200.0 term loan during the quarter. It reported approximately $1,495.0 available through its revolving credit facility and commercial-paper program.
- Operating cash flow was lower year over year, as higher working capital—particularly receivables after reducing factoring and incentive-compensation payments—partly offset increased cash earnings. The cash conversion cycle increased two days to 28.
- Financing cash use was $209.1, including $200.0 of debt repayment and $69.0 of dividends, partly offset by $59.9 from stock-option exercises. The quarterly dividend was increased 4% to $0.28375 per share. No shares were repurchased under the repurchase programs; 467 shares shown as purchased related to tax withholding.
Material changes, outlook and risks
- Consumer Domestic sales increased 4.3%, Consumer International 10.6%, and SPD 1.0%. Management cited growth in brands including Therabreath, Hero and Arm & Hammer; declines included Vitafusion/L’il Critters and Waterpik in Consumer Domestic.
- The company expects 2024 capital expenditures of approximately $180.0, primarily for laundry and litter manufacturing capacity. Management expects operating cash and borrowing capacity to fund planned capital spending, debt service, dividends and repurchases if implemented, and says it anticipates continued compliance with its maximum-leverage covenant. No specific earnings or sales guidance is provided in the filing text.
- In March, the company agreed to acquire Japan-based distributor Graphico for an estimated $35.0; closing was expected later in 2024. It also exited the MEGALAC supplement product line in SPD during Q1.
- Management flagged potential impairment sensitivity in the Waterpik trade name: its fair value was 109% of carrying value in the October 2023 test, with demand, competition from value brands and tariffs among the pressures discussed. The Vitafusion/L’il Critters trade name was also identified as potentially susceptible to impairment; its fair value was 154% of carrying value in that test.
- Other disclosed risks include economic and consumer-demand weakness, inflation, competition and retailer actions, supply-chain and labor disruption, commodity and foreign-exchange volatility, and pending or threatened legal and regulatory matters. The company states outcomes and damages in legal matters may not be predictable or estimable.
Most important facts for investors to verify
- Whether sales growth and gross-margin gains persist as marketing and SG&A spending increase.
- Waterpik and vitamin-brand performance against the assumptions and valuation headroom in the latest impairment tests.
- Working-capital and cash-conversion trends, including the effect of reduced receivables factoring.
- Completion, price and expected contribution of the Graphico acquisition, and delivery of the planned capacity investment.
- Debt, liquidity and covenant headroom, alongside the company’s dividend and any future share-repurchase decisions.